UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA

PROTECT THE PUBLIC'S TRUST 712 H Street, N.E. Suite 1682 Washington, D.C. 20002, Plaintiff, v. U.S. FOOD AND DRUG ADMINISTRATION 10903 New Hampshire Avenue. Silver Spring, MD 20993 Defendant.	)	Civil Case No. 1:23-cv-02378

COMPLAINT

1. Plaintiff Protect the Public's Trust brings this action against the U.S. Food and Drug Administration under the Freedom of Information Act, 5 U.S.C. § 552 ("FOIA"), seeking relief to compel compliance with the requirements of FOIA.

JURISDICTION AND VENUE

2. This Court has jurisdiction over this action pursuant to 5 U.S.C. § 552(a)(4)(B) and 28 U.S.C. § 1331.

3. Venue is proper in this Court pursuant to 5 U.S.C. § 552(a)(4)(B) and 28 U.S.C. § 1391(e).

PARTIES

4. Plaintiff Protect the Public's Trust ("PPT") is a nonprofit corporation dedicated to restoring public trust in government by promoting the fair and equal application of the rules and standards of ethical conduct to all public servants. Consistent with Justice Brandeis's aphorism that "Sunlight is said to be the best of disinfectants; electric light the most efficient policeman," PPT seeks to promote transparency and broadly disseminate

information so that the American people can evaluate the integrity and ethical conduct of those who act in their name. Louis Brandeis, OTHER PEOPLE'S MONEY AND HOW BANKERS USE IT (1914), https://louisville.edu/law/library/special-collections/the-louis-d.-brandeis-collection/other-peoples-money-chapter-v.

5. Defendant U.S. Food and Drug Administration ("FDA") is a federal agency within the meaning of FOIA, 5 U.S.C. § 552(f)(1). FDA has possession, custody, and control of records responsive to PPT's FOIA request.

STATEMENT OF FACTS

6. As Attorney General Garland has made clear, FOIA is "a vital tool for ensuring transparency, accessibility, and accountability in government" whose "'basic purpose . . . is to ensure an informed citizenry,' which is 'vital to the functioning of a democratic society [and] needed to check against corruption and to hold the governors accountable to the governed.'" Merrick Garland, *Memorandum for Heads of Executive Departments and Agencies: Freedom of Information Act Guidelines*, 1 (Mar. 15, 2022) (quoting *Nat'l Labor Rels. Bd. v. Robbins Tire & Rubber Co.*, 437 U.S. 214, 242 (1978)) ("Garland Memo").

I. FOIA Request Control # 2023-3161

7. On or about April 17, 2023, PPT submitted a FOIA request (attached as Exhibit A) to FDA seeking the following:

> From January 1, 2020, through April 12, 2023, records of communications between the identified special interest groups, also referred to as patient and consumer advocacy groups, and the list of FDA officials pertaining to those groups' input on proposed Animal Drug User Fee and Animal Generic Drug User Fee commitments.
>
> Center for Veterinary Medicine Officials:
> a) Director Tracey Forfa, JD
> b) Associate Director Roxanne Schweitzer
> c) Director Matthew Lucia, DVM
> d) Director, Timothy Schell, PhD

e) Director Regina Tan, DVM, MS
f) Director Dorothy Bailey, DVM (Acting)

Organizations:

1. Animal Equality
2. Animal Legal Defense Fund (ALDF)
3. Animal Liberation Front (ALF)
4. Animal Rights National Conference
5. The Animal Welfare Institute (AWI)
6. The Animal Welfare League (AWL)
7. Center for Biological Diversity (CBD)
8. Compassion in World Farming (CIWF)
9. Farm Sanctuary
10. Humane Research Council (HRC)
11. Humane Society of the United States (HSUS)
12. In Defense of Animals (IDA)
13. International Fund for Animal Welfare (IFAW)
14. The Jane Goodall Institute
15. Mercy for Animals
16. The Nonhuman Rights Project
17. People for the Ethical Treatment of Animals (PETA)
18. Physicians Committee for Responsible Medicine (PCRM)
19. Sea Shepherd Conservation Society
20. The Wildlife Conservation Society (WCS)

8. The release of these documents is in the public interest because they will help the public understand the process of advocacy group input associated with FDA user fees on proposed Animal Drug User Fee and Animal Generic Drug User commitments, including from animal drug product user fees. Animal Drugs and Feeds user fees are anticipated to total $58 million in FY2023. *See* Congressional Research Service, *The Food and Drug Administration (FDA) Budget: Fact Sheet* at 5 (Dec. 9, 2022), https://crsreports.congress.gov/product/pdf/R/R44576. The records sought by this request will promote transparency of such fee programs including FDA's user fee negotiations. United States Food and Drug Administration, *FDA: User Fees Explained* (Oct. 3, 2022), https://www.fda.gov/industry/fda-user-fee-programs/fda-user-fees-explained.

9. On April 19, 2023, PPT received an email entitled, "FDA Receipt of FOIA Request Control # 2023-3161," including an Acknowledgement Letter.

10. In its Acknowledgement Letter, FDA indicated "[w]e will respond as soon as possible" but "[d]ue to an increase in the number of incoming requests, we may be unable to comply with the twenty-working-day time limit in this case, as well as the ten additional days provided by the FOIA."

11. On May 12, 2023, having received no update on FOIA Request Control # 2023-3161, PPT contacted FDA and inquired, "[p]lease also provide any updates you may have on the search process."

12. On June 5, 2023, the FDA responded indicating only that PPT's request "is pending with our Center for Veterinary Medicine."

13. As the Garland Memo makes clear, "Timely disclosure of records is also essential to the core purpose of FOIA." Garland Memo, at 3.

14. As the record described above indicates, more than 115 days have elapsed since the FDA acknowledged receipt of PPT's request.

15. Yet the FDA still has not made a determination of whether it will comply with PPT's request. *See Citizens for Responsibility and Ethics in Washington v. Fed. Election Comm'n*, 711 F.3d 180 (D.C. Cir. 2013). The FDA has not produced responsive documents to PPT, has not communicated to PPT the scope of the documents it intends to produce and withhold, along with the reasons for such withholding, and has not informed PPT of its ability to appeal any adverse portion of its determination.

16. Through the FDA's failure to make a determination within the time period required by law, PPT has constructively exhausted its administrative remedies and seeks immediate judicial review.

II. FOIA Request Control # 2023-3162

17. On or about April 17, 2023, PPT submitted a FOIA request (attached as Exhibit B) to FDA seeking the following:

> From January 1, 2020, through April 12, 2023, records of communications between the identified special interest groups, also referred to as patient and consumer advocacy groups, and the list of FDA officials pertaining to those groups' input on proposed tobacco user fee commitments.
>
> Center for Tobacco Products officials:
> a) Director, Dr. Brian King
> b) Deputy Director, Michele Mital
> c) Janelle R. Barth
> d) Kathleen Crosby
> e) Matthew Farrelly, Ph.D.
> f) May Nelson
> g) Ann Simoneau
>
> Organizations:
> 1. Bloomberg Philanthropies
> 2. Bloomberg Initiative to Reduce Tobacco Use
> 3. Bill and Melinda Gates Foundation
> 4. Bureau of Investigative Journalism
> 5. CDC Foundation
> 6. Global Centre for Good Governance in Tobacco Control
> 7. International Union Against Tuberculosis and Lung Disease
> 8. Johns Hopkins University Bloomberg School of Public Health
> 9. New Venture Fund
> 10. Stopping Tobacco Organization and Products (STOP)
> 11. Vital Strategies
> 12. University of Bath
> 13. University of Illinois at Chicago
> 14. World Health Organization Tobacco-Free Initiative

18. The release of these documents is in the public interest because they will help the public understand the process of advocacy group input associated with FDA user fees from

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.